Table 3.

Individual study data, pooled dataset, and pooled analysis of survival data in relation to MMR and BRAFMT status

dMMRpMMRBRAFMTBRAFWT
CAIRO
Number of patients1830425297
 PFSmo. (95% CI)5.7 (4.2–8.8)6.9 (6.2–7.9)5.1 (4.1–7.7)7.0 (6.3–8.2)
HR (95% CI)1.34 (0.81–2.22)1.57 (1.03–2.38)
 OSmo. (95% CI)14.8 (12.0–26.0)17.9 (16.1–19.2)11.3 (8.3–15.0)18.1 (16.2–19.4)
HR (95% CI)1.26 (0.74–2.16)2.20 (1.43–3.38)
CAIRO2
Number of patients2948745471
 PFSmo. (95% CI)7.5 (6.4–10.5)10.5 (9.6–11.4)6.9 (6.2–8.5)10.6 (9.7–11.8)
HR (95% CI)1.66 (1.13–2.45)2.03 (1.48–2.79)
 OSmo. (95% CI)15.6 (12.9–22.3)22.0 (20.3–24.1)13.1 (10.7–16.5)22.4 (21.0–24.9)
HR (95% CI)1.60 (1.07–2.40)2.30 (1.65–3.20)
COIN
Number of patients651,3961201,341
 PFSmo. (95% CI)5.7 (5.4–6.1)6.5 (6.2–6.8)5.8 (5.6–6.2)6.5 (6.3–6.9)
HR (95% CI)1.56 (1.20–2.02)1.38 (1.14–1.68)
 OSmo. (95% CI)10.7 (9.3–13.0)16.0 (15.0–16.9)10.2 (9.0–11.7)16.5 (15.3–17.1)
HR (95% CI)1.80 (1.37–2.37)2.02 (1.65–2.48)
FOCUS
Number of patients4172360704
 PFSmo. (95% CI)8.1 (6.5–9.1)8.0 (7.4–8.3)8.1 (6.8–8.9)8.0 (7.4–8.3)
HR (95% CI)0.98 (0.71–1.35)0.98 (0.74–1.28)
 OSmo. (95% CI)16.6 (13.6–21.7)15.5 (14.5–16.6)12.3 (10.5–14.8)15.7 (14.8–17.0)
HR (95% CI)0.90 (0.64–1.27)1.52 (1.15–2.00)
Pooled dataset
Number of patients1532,9102502,813
 PFSmo. (95% CI)6.2 (5.9–7.0)7.6 (7.3–8.0)6.2 (6.0–6.8)7.7 (7.4–8.0)
HR (95% CI)1.33 (1.12–1.57)1.34 (1.17–1.54)
 OSmo. (95% CI)13.6 (12.4–15.6)16.8 (16.3–17.5)11.4 (10.5–12.4)17.2 (16.7–18.0)
HR (95% CI)1.35 (1.13–1.61)1.91 (1.66–2.19)

NOTE: Statistically significant results are shown in bold.

Abbreviations: mo., median PFS and OS time in months; mt, mutant tumor; wt, wild-type tumor.